Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
Share this
Recent posts
-
ASCO 2026: Multi-agent LLM framework predicts one-year risk across multiple cancers
-
ASCO 2026: Benchmarking US oncology populations and survival using multi-health system EHR data
-
ASCO 2026: Breast cancer screening and detection after 2024 guideline expansion for women in their 40s
-
ASCO 2026: Prostate cancer screening and earlier-stage diagnosis in real-world data
-
Four real-world findings on early cancer detection
Follow Truveta
Stay up-to-date